nach oben

Seminars in Immunopathology

Erschienen in:

01.11.2014 | Review

CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity

verfasst von: Eugenia Corrales-Aguilar, Katja Hoffmann, Hartmut Hengel

Erschienen in: Seminars in Immunopathology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The constant region of IgG antibodies mediates antiviral activities upon engaging host Fcγ receptors (FcγRs) expressed by a variety of immune cells, such as antibody-dependent cellullar cytotoxcity (ADCC) executed by natural killer (NK)cells. Human cytomegalovirus (HCMV) is unique among viruses by encoding also an array of several Fcγ-binding glycoproteins with cell surface disposition and concomitant incorporation into the virion. Evidence is increasing that the virus-encoded Fcγ receptors differ in their Fcγ binding mode but effectively operate as adversaries of host FcγRs since they are able to prevent IgG-mediated triggering of activating host FcγRs, i.e., FcγRI, FcγRIIA, and FcγRIIIA. Here we discuss virus-encoded FcγRs as the first known HCMV inhibitors of IgG-mediated immunity which could account for the limited efficacy of HCMV hyperimmune globulin in clinical settings. A better understanding of their molecular mode of action opens up new perspectives for improving IgG therapies against HCMV disease.

Chee MS, Bankier AT, Beck S et al (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125–69PubMed

Davison AJ, Dolan A, Akter P et al (2003) The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 84:17–28PubMed

Murphy E, Yu D, Grimwood J et al (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 100:14976–81. doi:10.1073/pnas.2136652100 PubMedPubMedCentral

Stern-Ginossar N, Gur C, Biton M et al (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065–73. doi:10.1038/ni.1642 PubMed

Goodrum F, Reeves M, Sinclair J et al (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937–45. doi:10.1182/blood-2007–01–070078 PubMedPubMedCentral

Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–38. doi:10.1016/S1473–3099(04)01202–2 PubMed

Ji Y-N, An L, Zhan P, Chen X-H (2012) Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 39:6537–46. doi:10.1007/s11033–012–1482–6 PubMed

Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E (2012) The impact of CMV infection on survival in older humans. Curr Opin Immunol 24:507–11. doi:10.1016/j.coi.2012.04.002 PubMed

Cobbs CS (2013) Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 25:682–8. doi:10.1097/CCO.0000000000000005 PubMed

10.

Reddehase MJ, Mutter W, Münch K et al (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–8PubMedPubMedCentral

11.

Polić B, Hengel H, Krmpotić A et al (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047–54PubMedPubMedCentral

12.

Jonjić S, Pavić I, Polić B et al (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713–7PubMed

13.

Klenovsek K, Weisel F, Schneider A et al (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–9. doi:10.1182/blood-2007–06–095414 PubMed

14.

Hengel H, Brune W, Koszinowski UH (1998) Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist. Trends Microbiol 6:190–7PubMed

15.

Mocarski ES (2004) Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707–717. doi:10.1111/j.1462–5822.2004.00425.x PubMed

16.

Scalzo A, Corbett A (2007) The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol cell … 46–54. doi: 10.1038/sj.icb.7100013

17.

Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2:706–13. doi:10.1038/nri891 PubMed

18.

Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–42. doi:10.1146/annurev-immunol-032712–095916 PubMed

19.

Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77:195–262PubMed

20.

Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179–204. doi:10.1016/S0065–2776(07)96005–8 PubMed

21.

Pincetic A, Bournazos S, DiLillo DJ et al (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707–716. doi:10.1038/ni.2939 PubMed

22.

Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236:265–75. doi:10.1111/j.1600–065×.2010.00910.x PubMed

23.

Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47. doi:10.1038/nri2206 PubMed

24.

Takai T, Ono M, Hikida M et al (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346–9. doi:10.1038/379346a0 PubMed

25.

Bolland S, Ravetch JV (1999) Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 72:149–77PubMed

26.

Karsten CM, Pandey MK, Figge J et al (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med 18:1401–6. doi:10.1038/nm.2862 PubMedPubMedCentral

27.

Nimmerjahn F, Ravetch JV (2011) FcγRs in health and disease. Curr Top Microbiol Immunol 350:105–25. doi:10.1007/82_2010_86 PubMed

28.

Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–90. doi:10.1146/annurev.immunol.19.1.275 PubMed

29.

Lu J, Marjon KD, Mold C et al (2012) Pentraxins and Fc receptors. Immunol Rev 250:230–8. doi:10.1111/j.1600–065×.2012.01162.x PubMedPubMedCentral

30.

Du Clos TW (2013) Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013:379040. doi:10.1155/2013/379040 PubMedPubMedCentral

31.

Lu J, Marnell LL, Marjon KD et al (2008) Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456:989–92. doi:10.1038/nature07468 PubMedPubMedCentral

32.

Ernst LK, van de Winkel JG, Chiu IM, Anderson CL (1992) Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem 267:15692–700PubMed

33.

Warmerdam PA, Nabben NM, van de Graaf SA et al (1993) The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem 268:7346–9PubMed

34.

Ory PA, Clark MR, Kwoh EE et al (1989) Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 84:1688–91. doi:10.1172/JCI114350 PubMedPubMedCentral

35.

Guilliams M, Bruhns P, Saeys Y et al (2014) The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 14:94–108. doi:10.1038/nri3582 PubMed

36.

Hogarth PM, Pietersz GA (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11:311–31. doi:10.1038/nrd2909 PubMed

37.

Bruhns P, Iannascoli B, England P et al (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–25. doi:10.1182/blood-2008–09–179754 PubMed

38.

Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–9. doi:10.1182/blood-2012–01–380121 PubMed

39.

Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9:457–92. doi:10.1146/annurev.iy.09.040191.002325 PubMed

40.

Pan LY, Mendel DB, Zurlo J, Guyre PM (1990) Regulation of the steady state level of Fc gamma RI mRNA by IFN-gamma and dexamethasone in human monocytes, neutrophils, and U-937 cells. J Immunol 145:267–75PubMed

41.

Veri M-C, Gorlatov S, Li H et al (2007) Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121:392–404. doi:10.1111/j.1365–2567.2007.02588.x PubMedPubMedCentral

42.

Ehrhardt GRA, Cooper MD (2011) Immunoregulatory roles for fc receptor-like molecules. Curr Top Microbiol Immunol 350:89–104. doi:10.1007/82_2010_88 PubMed

43.

Cassard L, Jönsson F, Arnaud S, Daëron M (2012) Fcγ receptors inhibit mouse and human basophil activation. J Immunol 189:2995–3006. doi:10.4049/jimmunol.1200968 PubMed

44.

Van der Heijden J, Breunis WB, Geissler J et al (2012) Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 188:1318–24. doi:10.4049/jimmunol.1003945 PubMed

45.

Zhao W, Kepley CL, Morel PA et al (2006) Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol 177:694–701PubMedPubMedCentral

46.

Magnusson SE, Engström M, Jacob U et al (2007) High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis. Arthritis Res Ther 9:R51. doi:10.1186/ar2206 PubMedPubMedCentral

47.

Metes D, Manciulea M, Pretrusca D et al (1999) Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells. Eur J Immunol 29:2842–52. doi:10.1002/(SICI)1521–4141(199909)29:09<2842::AID-IMMU2842>3.0.CO;2–5 PubMed

48.

Meknache N, Jönsson F, Laurent J et al (2009) Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor FcgammaRIIIB (CD16B). J Immunol 182:2542–50. doi:10.4049/jimmunol.0801665 PubMed

49.

Flinsenberg TWH, Compeer EB, Koning D et al (2012) Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood 120:5163–72. doi:10.1182/blood-2012–06–434498 PubMed

50.

Tridandapani S, Wardrop R, Baran CP et al (2003) TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J Immunol 170:4572–7PubMed

51.

Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–25. doi:10.1038/nri2155 PubMed

52.

Ghetie V, Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592–8PubMed

53.

Rath T, Kuo TT, Baker K et al (2013) The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 33(Suppl 1):S9–17. doi:10.1007/s10875–012–9768-y PubMed

54.

Ko S-Y, Pegu A, Rudicell RS et al (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. doi:10.1038/nature13612 PubMed

55.

Woof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4:89–99. doi:10.1038/nri1266 PubMed

56.

Hulett MD, Osman N, McKenzie IF, Hogarth PM (1991) Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG. J Immunol 147:1863–8PubMed

57.

Zhang Y, Boesen CC, Radaev S et al (2000) Crystal structure of the extracellular domain of a human Fc gamma RIII. Immunity 13:387–95PubMed

58.

Sondermann P, Huber R, Jacob U (1999) Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J 18:1095–103. doi:10.1093/emboj/18.5.1095 PubMedPubMedCentral

59.

Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267–73. doi:10.1038/35018508 PubMed

60.

Hamerman JA, Lanier LL (2006) Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006:re1. doi: 10.1126/stke.3202006re1

61.

Sulica A, Herberman RB (1996) Cytophilic immunoglobulins revisited via natural killer cells. FASEB J 10:1495–504PubMed

62.

Lux A, Yu X, Scanlan CN, Nimmerjahn F (2013) Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol 190:4315–23. doi:10.4049/jimmunol.1200501 PubMed

63.

Shields RL, Lai J, Keck R et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–40. doi:10.1074/jbc.M202069200 PubMed

64.

Niwa R, Natsume A, Uehara A et al (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306:151–60. doi:10.1016/j.jim.2005.08.009 PubMed

65.

Niwa R, Sakurada M, Kobayashi Y et al (2005) Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327–36. doi:10.1158/1078–0432.CCR-04–2263 PubMed

66.

Okazaki A, Shoji-Hosaka E, Nakamura K et al (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336:1239–49. doi:10.1016/j.jmb.2004.01.007 PubMed

67.

Radaev S, Motyka S, Fridman WH et al (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469–77. doi:10.1074/jbc.M100350200 PubMed

68.

Langone JJ (1982) Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol 32:157–252PubMed

69.

Müller MG, Ing JY, Cheng MK-W et al (2013) Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis. J Immunol 191:3287–96. doi:10.4049/jimmunol.1301153 PubMedPubMedCentral

70.

Cortese M, Calò S, D’Aurizio R et al (2012) Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. PLoS One 7:e50166. doi:10.1371/journal.pone.0050166 PubMedPubMedCentral

71.

Atalay R, Zimmermann A, Wagner M et al (2002) Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 76:8596–608PubMedPubMedCentral

72.

Lilley BN, Ploegh HL, Tirabassi RS (2001) Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J Virol 75:11218–21. doi:10.1128/JVI.75.22.11218–11221.2001 PubMedPubMedCentral

73.

Frank I, Friedman HM (1989) A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 63:4479–88PubMedPubMedCentral

74.

Lenac T, Budt M, Arapovic J et al (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203:1843–50. doi:10.1084/jem.20060514 PubMedPubMedCentral

75.

Sprague ER, Reinhard H, Cheung EJ et al (2008) The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 82:3490–9. doi:10.1128/JVI.01476–07 PubMedPubMedCentral

76.

Thäle R, Lucin P, Schneider K et al (1994) Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol 68:7757–65PubMedPubMedCentral

77.

Budt M, Reinhard H, Bigl A, Hengel H (2004) Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG? Int Immunopharmacol 4:1135–48. doi:10.1016/j.intimp.2004.05.020 PubMed

78.

Namboodiri AM, Budkowska A, Nietert PJ, Pandey JP (2007) Fc gamma receptor-like hepatitis C virus core protein binds differentially to IgG of discordant Fc (GM) genotypes. Mol Immunol 44:3805–8. doi:10.1016/j.molimm.2007.03.022 PubMedPubMedCentral

79.

Mercé-Maldonado E (2011) Identification and functional characterization of a novel HCMV-encoded Fcγ receptor blocking CD16-mediated activation of human natural killer cells. Heinrich-Heine-Universität, Düsseldorf

80.

Corrales-Aguilar E, Trilling M, Hunold K et al (2014) Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog 10:e1004131. doi:10.1371/journal.ppat.1004131 PubMedPubMedCentral

81.

Cha TA, Tom E, Kemble GW et al (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70:78–83PubMedPubMedCentral

82.

Varnum SM, Streblow DN, Monroe ME et al (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960–6. doi:10.1128/JVI.78.20.10960–10966.2004 PubMedPubMedCentral

83.

Dargan DJ, Douglas E, Cunningham C et al (2010) Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 91:1535–46. doi:10.1099/vir.0.018994–0 PubMedPubMedCentral

84.

Dolan A, Cunningham C, Hector RD et al (2004) Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:1301–12PubMed

85.

Akter P, Cunningham C, McSharry BP et al (2003) Two novel spliced genes in human cytomegalovirus. J Gen Virol 84:1117–22PubMed

86.

Stanton RJ, Baluchova K, Dargan DJ et al (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191–208. doi:10.1172/JCI42955 PubMedPubMedCentral

87.

Crnković-Mertens I, Messerle M, Milotić I et al (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72:1377–82PubMedPubMedCentral

88.

Arapovic J, Lenac T, Antulov R et al (2009) Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus. J Virol 83:8198–207. doi:10.1128/JVI.02549–08 PubMedPubMedCentral

89.

Mintern JD, Klemm EJ, Wagner M et al (2006) Viral interference with B7–1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J Immunol 177:8422–31PubMed

90.

Westmoreland D, Watkins JF (1974) The IgG receptor induced by herpes simplex virus: studies using radioiodinated IgG. J Gen Virol 24:167–78PubMed

91.

Yasuda J, Milgrom F (1968) Hemadsorption by herpes simplex-infected cell cultures. Int Arch Allergy Appl Immunol 33:151–70PubMed

92.

Watkins JF (1964) Asorption of sensitized sheep erytrocytes to Hela cells infected with herpes simplex virus. Nature 202:1364–5PubMed

93.

Dubin G, Socolof E, Frank I, Friedman HM (1991) Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 65:7046–50PubMedPubMedCentral

94.

Nagashunmugam T, Lubinski J, Wang L et al (1998) In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72:5351–9PubMedPubMedCentral

95.

Sprague ERE, Wang C, Baker D, Bjorkman PJP (2006) Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 4:e148. doi:10.1371/journal.pbio.0040148 PubMedPubMedCentral

96.

Wiger D, Michaelsen TE (1985) Binding site and subclass specificity of the herpes simplex virus type 1-induced Fc receptor. Immunology 54:565–72PubMedPubMedCentral

97.

Sondermann P, Oosthuizen V (2002) X-ray crystallographic studies of IgG-Fc gamma receptor interactions. Biochem Soc Trans 30:481–486PubMed

98.

Kutza AS, Muhl E, Hackstein H et al (1998) High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 26:1076–82PubMed

99.

Ross SA, Arora N, Novak Z et al (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386–9. doi:10.1086/649903 PubMedPubMedCentral

100.

Hansen SG, Powers CJ, Richards R et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–6. doi:10.1126/science.1185350 PubMedPubMedCentral

101.

Corrales-Aguilar E, Trilling M, Reinhard H et al (2013) A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods 387:21–35. doi:10.1016/j.jim.2012.09.006 PubMed

102.

Linde GA, Hammarström L, Persson MA et al (1983) Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun 42:237–44PubMedPubMedCentral

103.

Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Biologicals 24:117–24. doi:10.1006/biol.1996.0015 PubMed

104.

Lubinski JM, Lazear HM, Awasthi S et al (2011) The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J Virol 85:3239–49PubMedPubMedCentral

105.

Ryckman BJ, Chase MC, Johnson DC (2008) HCMV gH/gL/UL128–131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci U S A 105:14118–23. doi:10.1073/pnas.0804365105 PubMedPubMedCentral

106.

Spiller OB, Morgan BP, Tufaro F, Devine DV (1996) Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol 26:1532–8. doi:10.1002/eji.1830260719 PubMed

107.

Hwang I, Zhang T, Scott JM et al (2012) Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol 24:793–802. doi:10.1093/intimm/dxs080 PubMedPubMedCentral

108.

Zhang T, Scott JM, Hwang I, Kim S (2013) Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J Immunol 190:1402–6. doi:10.4049/jimmunol.1203034 PubMedPubMedCentral

109.

Gumá M, Angulo A, Vilches C et al (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664–71. doi:10.1182/blood-2004–05–2058 PubMed

110.

Gumá M, Budt M, Sáez A et al (2006) Expansion of CD94/NKG2C + NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107:3624–31. doi:10.1182/blood-2005–09–3682 PubMed

111.

Wu Z, Sinzger C, Frascaroli G et al (2013) Human cytomegalovirus-induced NKG2C (hi) CD57 (hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 87:7717–25. doi:10.1128/JVI.01096–13 PubMedPubMedCentral

112.

Boeckh M, Bowden RA, Storer B et al (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343–51PubMed

113.

Hodson EM, Jones CA, Strippoli GFM, et al. (2007) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane database Syst Rev CD005129. doi: 10.1002/14651858.CD005129.pub2

114.

Raanani P, Gafter-Gvili A, Paul M et al (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 27:770–81. doi:10.1200/JCO.2008.16.8450 PubMed

115.

Revello MG, Lazzarotto T, Guerra B et al (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316–26. doi:10.1056/NEJMoa1310214 PubMed

116.

Schoppel K, Kropff B, Schmidt C et al (1997) The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175:533–44PubMed

117.

Powers C, Früh K (2008) Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 197:109–15. doi:10.1007/s00430–007–0073-y PubMedPubMedCentral

118.

Mocarski ES (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10:332–9PubMed

119.

Babic M, Polic B, Krmpotic A et al (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20:30–38. doi:10.1016/j.coi.2007.11.002 PubMedPubMedCentral

120.

Hengel H, Koszinowski UH (1997) Interference with antigen processing by viruses. Curr Opin Immunol 9:470–6PubMed

121.

Halenius A, Gerke C, Hengel H (2014) Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell. Mol, Immunol

122.

Manley K, Anderson J, Yang F et al (2011) Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10:197–209PubMed

123.

Letourneur F, Klausner RD (1992) A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 69:1143–57PubMed

Titel: CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity
verfasst von: Eugenia Corrales-Aguilar
Katja Hoffmann
Hartmut Hengel
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Seminars in Immunopathology / Ausgabe 6/2014
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-014-0448-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Editorial introduction for Seminars in Immunopathology special issue on “Immune modulation, properties and models of CMV”

Manipulation of host pathways by human cytomegalovirus: insights from genome-wide studies

Models of vertical cytomegalovirus (CMV) transmission and pathogenesis

The use of microRNA by human viruses: lessons from NK cells and HCMV infection